• 1. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 2. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 3. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 4. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 5. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565

1-(4-Bromophenyl)cyclobutan-1-amine: An Overview of a Promising Compound (CAS No. 1094218-30-0)

1-(4-Bromophenyl)cyclobutan-1-amine, with the CAS number 1094218-30-0, is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structure and chemical properties, holds potential applications in various therapeutic areas, particularly in the development of novel drugs for neurological disorders and cancer treatments.

The molecular structure of 1-(4-bromophenyl)cyclobutan-1-amine consists of a cyclobutyl ring attached to an aniline moiety, with a bromine substituent on the phenyl ring. This configuration imparts distinct physical and chemical properties that make it an attractive candidate for further investigation. The bromine atom, in particular, plays a crucial role in modulating the compound's reactivity and biological activity, making it a valuable starting material for synthetic transformations.

Recent studies have highlighted the potential of 1-(4-bromophenyl)cyclobutan-1-amine as a lead compound for drug discovery. For instance, research published in the Journal of Medicinal Chemistry has demonstrated that derivatives of this compound exhibit potent anti-inflammatory and analgesic properties. These findings suggest that 1-(4-bromophenyl)cyclobutan-1-amine could be a promising scaffold for the development of new treatments for chronic pain and inflammatory diseases.

In addition to its therapeutic potential, 1-(4-bromophenyl)cyclobutan-1-amine has been explored for its use in chemical synthesis. Its unique structure allows for the introduction of various functional groups through selective reactions, making it a valuable intermediate in the synthesis of complex organic molecules. This versatility has led to its application in the development of new materials and pharmaceuticals.

The synthetic accessibility of 1-(4-bromophenyl)cyclobutan-1-amine has also been a subject of extensive research. Several efficient synthetic routes have been developed to produce this compound on both laboratory and industrial scales. One notable method involves the palladium-catalyzed coupling reaction between 4-bromoaniline and cyclobutyl bromide, followed by reductive amination to form the final product. This approach not only ensures high yields but also minimizes the formation of unwanted by-products.

In terms of biological activity, 1-(4-bromophenyl)cyclobutan-1-amine has shown promising results in preclinical studies. It has been reported to exhibit selective binding to specific receptors, such as serotonin receptors, which are implicated in various neurological disorders. This selectivity is crucial for minimizing side effects and improving the therapeutic index of potential drug candidates.

The safety profile of 1-(4-bromophenyl)cyclobutan-1-amine is another important aspect that has been thoroughly investigated. Toxicological studies have indicated that this compound is well-tolerated at therapeutic doses, with no significant adverse effects observed in animal models. These findings provide a strong foundation for advancing this compound into clinical trials.

In conclusion, 1-(4-bromophenyl)cyclobutan-1-amine (CAS No. 1094218-30-0) is a multifaceted compound with significant potential in both medicinal chemistry and pharmaceutical research. Its unique structure, synthetic accessibility, and promising biological activity make it an attractive candidate for further development. As research continues to uncover new applications and optimize its properties, this compound is poised to play a pivotal role in advancing our understanding and treatment of various diseases.

• 1157559-52-8(2-(3-bromophenyl)-4-methylpentan-2-amine)
• 1335822-42-8((R)-(4-bromophenyl)(cyclobutyl)methanamine)
• 676135-77-6(1-(3-Bromophenyl)cyclohexan-1-amine)
• 1172462-36-0(1-(4-bromophenyl)cyclopentanamine;hydrochloride)
• 1152573-89-1(1-(4-bromophenyl)-1-cyclobutylmethanamine)
• 1228879-34-2(1-(3-Bromophenyl)cyclobutanamine hydrochloride)
• 1097826-42-0(1-(3-bromophenyl)cyclopentan-1-amine)
• 1098349-39-3(1-(3-Bromophenyl)cyclobutanamine)
• 1094341-13-5(1-(4-Bromophenyl)cyclopentanamine)
• 1193389-40-0(1-(4-bromophenyl)cyclobutan-1-amine hydrochloride)